# Run Notes

## Run metadata

- Model: Claude Opus 5.5 (model ID `claude-opus-5-5`), running as a Claude Code subagent.
- Run date: 2026-09-26 (session date). Review written as of the stated submission date, 2025-08-17; only literature published before that date was used (all sources cited are 2004–2020).
- Skill followed: `prcase/skill/SKILL.md`, initial-review mode. Files read: `references/workflow.md`, `references/review-framework.md`, `references/review-dossier-template.md`, `references/review-template.md`, `references/style-profile.md` (before drafting), `references/final-pruning.md` (only after the complete S4 draft existed, as instructed). `references/revision-review.md` was not read: not applicable to an initial review.
- Stages executed: S0 → S1 → S2 → S3 → S4 → S5, in order, with dossier sections written for each.
- Outputs: `peer-review.md` (reviewer-facing, English), `review-dossier.md` (confidential), `run-notes.md` (this file). Working files (extracted text, rendered figure pages) are under `ai_review/work/`.

## Manuscript handling

- Source: `C/blind/preprint_v1.pdf`, 65 pages, the only manuscript material used.
- `pdftotext` is not installed on this machine. Text was extracted with PyMuPDF (`fitz`) page by page, and line-number-only lines from the manuscript margin were stripped for readability. Figure and table pages (PDF pages 50–65) were rendered at 110 dpi and inspected visually; all p-values and panel structures cited in the review were read from those renderings.
- Extraction artifacts noted and not treated as manuscript errors: Greek letters in cytokine names (IFNγ, TGFβ, FcγR) are dropped by the extractor; reference numbers are merged into text; Extended Data Table 3a is a dense grid that was read from the rendered image.

## Missing materials (judgments marked Not assessable)

- Trial protocol and statistical analysis plan — not provided. Whether the "significant" between-arm safety comparison, the DCB definition, and the biomarker analyses were pre-specified could not be verified; the review asks the authors to state this.
- Methods Figure 1 (ipilimumab ELISA schematic) and Methods Table 2 (blood flow-cytometry antibody panel) — the corresponding PDF pages contain only the captions. Flagged as a minor comment rather than judged.
- First/last enrolment dates, data-lock date, CONSORT checklist — absent from the submitted file.
- No separate supplementary files were referenced by the manuscript beyond Extended Data, which is included.
- Availability of germline DNA for FCGR3A genotyping is unknown, so that request was phrased conditionally and placed in Recommended Revisions rather than as a required action.

## Literature verified

All sources that materially affect a claim verdict or a request were verified against Europe PMC records (title, authors, journal, year, DOI/PMID, abstract text), not from memory. Full register with propositions is in the dossier (L1–L12). Key items:

- Larkin 2015, NEJM (PMID 26027431) — grade 3/4 TRAEs 16.3% nivolumab vs 55.0% combination. Used against the "equivalent to anti-PD1 monotherapy" claim.
- Lebbé 2019, JCO CheckMate 511 (PMID 30811280) — grade 3–5 TRAEs 34% vs 48%, ORR 45.6% vs 50.6%. Used as the dose-reduction benchmark.
- Goldmacher 2020, JCO itRECIST (PMID 32552274) — metadata and title verified; the abstract body was not returned by the API, so the review cites it only as the standardized framework for separate injected/non-injected assessment, which its title supports.
- Sharma 2019, Clin Cancer Res (PMID 30054281); Arce Vargas 2018, Cancer Cell (PMID 29576375); Romano 2015, PNAS (PMID 25918390) — the three poles of the human Treg-depletion controversy.
- Hamid 2011, J Transl Med (PMID 22123319) and Spranger 2013, Sci Transl Med (PMID 23986400) — used against the "unexpected" framing of the Treg/M2 finding.
- Tumeh 2014, Nature (PMID 25428505); Helmink 2020, Nature (PMID 31942075) — prior context for the adaptive-immunity associations.
- Ray 2016, Oncotarget (PMID 27391442) — abstract reports injected-lesion response 67%, abscopal response 89%, irRC ORR 40%; the manuscript presents the 40% as the abscopal rate. Basis for a minor citation-accuracy comment.
- Nature Portfolio clinical research policy (nature.com) — fetched via curl after WebFetch hit an authentication redirect. Confirms ICMJE registration before first enrolment, CONSORT conformance, and the requirement for exact enrolment and data-lock dates.

## Blinding

- Blinding risk encountered: page 3 of the preprint PDF carries a Research Square banner stating that a version of record was published in a journal, with its DOI. This was seen incidentally while reading the required manuscript file. I did not open, fetch, or search for that DOI, the published article, its peer review file, author responses, or any commentary, and no such material informed the review. This is recorded in the dossier's source set.
- Web searches were restricted to background literature and journal policy. One search result list (for the CheckMate 067/511 and itRECIST queries) contained only unrelated trials and the intended benchmark papers; nothing identifiable as the published version of this manuscript or reviews of it was opened.
- No directories other than `prcase/skill/` and `prcase/C/blind/` (plus the authorized `prcase/C/ai_review/` output folder) were read. `../reference/` and other case folders were not accessed.
- The manuscript is not author-blinded (it carries the full author list and affiliations). I did not use author identity in any judgment, and self-citation patterns were not raised as an issue.

## Skill points that were ambiguous or required a decision

1. **Journal fields.** The task specifies Nature, initial submission, but no review form, editor question, or recommendation option list was supplied. S0 requires these. I used the skill's default structure and standard Nature options, and recorded the assumption in the dossier.
2. **Word-length target.** `style-profile.md` sets 600–1,000 words as the default and 1,200 as a soft ceiling. The delivered report is ~1,840 words. The skill permits exceeding the range when independent critical issues cannot be merged; with four validity-critical issues plus a substantial list of numeric inconsistencies that a trial report must fix, compressing further would have dropped either a remedy or a verifiable discrepancy. The justification is recorded in the dossier's S5 section. This is the clearest tension between the style profile and the S3/S4 traceability requirements.
3. **S5 ordering.** `final-pruning.md` must not be read during S0–S3 and only after a complete draft exists. I wrote the dossier and the full draft first, then read it and pruned. This is visible in the run: the draft was rewritten once for compression, and no scientific content changed.
4. **Reading figure p-values.** The framework demands verified numbers, but the only source is rendered raster images. Values were legible at 110 dpi and are reported exactly; two items that were not fully legible (the Fig. 3i/3j log-rank p-values and the Fig. 3h bar heights) are described as approximate in the dossier and phrased as "appear"/omitted in the report.
5. **Recommendation logic vs. author-facing framing.** The skill forbids disguising a venue-fit judgment as a data-validity flaw. Here both exist: the claims are genuinely overstated (validity), and the calibrated paper is below the Nature bar (venue). The author-facing report states only the scientific gaps and the calibration required; the venue judgment sits in the Recommendation and the confidential comment.
6. No step of the skill failed to execute.

## Residual uncertainty

- Nature's policy page was read in 2026; its exact wording as of August 2025 was not independently verified, so the CONSORT/registration comment is framed as a reporting request rather than a policy violation finding.
- Whether any of the biomarker analyses were pre-specified is unknown; the review asks rather than asserts.
- The count of injected lesions (46) versus the count implied by the per-patient figures (≥48) may have an innocent explanation (e.g., lesions injected in patients later excluded); it is raised as a reconciliation request, not an error claim.
